Overview
Lobbying Costs
17,500€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
TRIVAROP (TRIVAROP)
EU Transparency Register
78758165752-12 First registered on 28 Apr 2011
Goals / Remit
Joris Vandeputte is specialised in biotechnology and vaccines particularly those fields related with innovation, international relations, development and Sustainable Development Goals, sanitary prevention,vaccination,zoonoses, one health policies, poverty related diseases such as Malaria, Tuberculosis, and humanitarian aid.
Joris Vandeputte particularly focuses on EU Innovation Union, HORIZON EUROPE and beyond, innovative solutions in Health, biotechnology with positive impact on added value creation.Main EU files targeted
- REGULATION (EU) 2016/429 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 9 March 2016: interaction with Commission and parliament on Rabies in the EU and neighboring countries
- HORIZON EUROPE: investment in poverty related diseases, interaction with Development CommitteeAddress
Head Office
de la Tannerie, 14
COLFONTAINE 7340
BELGIUM -
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 24 Nov 2024
Name Start date End Date Mr Joris VANDEPUTTE 17 Nov 2020 17 Nov 2021 Mr Joris VANDEPUTTE 13 Nov 2019 13 Nov 2020 Mr Joris VANDEPUTTE 15 Nov 2018 13 Nov 2019 Mr Joris VANDEPUTTE 28 Nov 2017 14 Nov 2018 Mr Joris VANDEPUTTE 15 Nov 2016 12 Nov 2017 Mr Joris VANDEPUTTE 17 Nov 2015 12 Nov 2016 Mr Joris VANDEPUTTE 11 Nov 2014 10 Nov 2015 Mr Joris VANDEPUTTE 08 Nov 2013 07 Nov 2014 Mr Joris VANDEPUTTE 22 Nov 2012 08 Nov 2013 Mr Joris VANDEPUTTE 18 Jan 2012 08 Feb 2013 Complementary Information
The part of time in direct relation with the Transparency register at the European Parliament is estimated at around 25% of the total activity, mainly IMI Project Zoonosis Anticipation Initiative (ZAPI) and Rabies control on behalf of IABS, Malaria Fund and activities related to ACP livestock disease control, control of COVID-19, Europe's sovereignty in vaccine development and production
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
I - Professional consultancies/law firms/self-employed consultants
Subcategory
Self-employed consultants
-
Networking
Affiliation
European TB coalition
Parliamentary working group on Innovation, Access to Medicines and Poverty-Related Diseases
IABS (International Alliance for Biological Standardisation), IABS-EU the European Affiliate of IABS
the African Forum in Brussels
Civil society on poverty related diseasesMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
17,500€
EU grant income for closed financial year
30,000 € (Source: IMI (Innovative Medecines Initiative))
Other financial info
Total turnover for all clients, activities related with transparency register (around € 20 000) and activities not related with transparency register (€ 170000)
Declared lobby clients
Client Name Amount IMI project ZAPI (Zoonosis Anticipation and Preparedness Initiative) 0€ - 9,999€ International Alliance for Biological Standardization (IABS) 0€ - 9,999€ World Organisation for Animal Health (OIE) 0€ - 9,999€ -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
- Strengthening animal health services in ACP countries, early warning for zoonotic and pandemic diseases
- Strengthening Europe's sovereignty for vaccine development and productionIMI program ZAPI (Zoonosis anticipation preparedness initiative) and REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on veterinary medicinal products and repealing Directive 2001/82/EC: interaction with. ENVI and EMA on innovation and platform technologies for vaccine and antibody development and production in case of pandemic emergencies
- EU 2020, competitive Europe with ENVI committee drafting arguments for investment in EU sovereignty in vaccine development and production in the COVID urgency
- Europe and poverty related diseases: EU malaria Fund presentation to DEV committeeOther activities
None declared
- Meetings
Meetings
None declared
- Meetings